Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

adverse cardiac events in patients (4.0 percent XIENCE V treated patients, 8.0 percent TAXUS treated patients, P-superior = 0.004). -- Reducing the number of retreatments in patients due to ischemia, or lack of blood supply (ischemic target lesion revascularization, TLR), (2.4 percent XIENCE V, 5.1 percent TAXUS, P-superior = 0.01). -- Reducing the amount of renarrowing in the vessel within the length of the stent (in-stent binary restenosis), (1.9 percent XIENCE V, 4.9 percent TAXUS, P-superior = 0.02). -- Reducing the amount of renarrowing in the vessel within the length of the stent plus 5 mm beyond the ends of the stent (in-segment restenosis), (4.1 percent XIENCE V, 7.8 percent TAXUS, P-superior = 0.04).

"The combination of long-term safety data from SPIRIT FIRST and superior efficacy data from SPIRIT II and SPIRIT III add to the growing body of evidence supporting the XIENCE V system as an important next-generation technology," said John M. Capek, Ph.D., senior vice president, Abbott Vascular. "We look forward to continuing to expand patient and physician access to the XIENCE V system around the world."

About XIENCE V

XIENCE V was launched in Europe and Asia Pacific in 2006. XIENCE V is currently an investigational device in the United States and Japan. Results from the SPIRIT III trial are intended to support U.S. Food and Drug Administration (FDA) approval of the XIENCE V Stent System and Ministry of Health, Labour and Welfare approval in Japan.

Abbott expects to complete Pre-Market Approval (PMA) submission of the XIENCE V system to the U.S. FDA in the second quarter of 2007.

The XIENCE V system utilizes everolimus, which has been shown to reduce tissue proliferation in coronary vessels following stent implantation, and one of the world's most popular metallic platforms -- the MULTI-LINK VISION Coronary Stent System.

XIENCE V
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/17/2014)... , September 17, 2014 ... GRC 17536, has shown positive data in a Phase ... diabetic neuropathy , Glenmark Pharmaceuticals ... Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown ... controlled, multi-centre, proof of concept study conducted on 138 ...
(Date:9/17/2014)...  Members of the physician IT team at ... today that the enterprise is working with ... capabilities and provide immediate cluster fail over in ... the Dicom Systems enterprise imaging solutions will be ... more effectively deliver the right images to the ...
(Date:9/17/2014)... 2014 An analysis done by the CVS ... (sofosbuvir), a new and expensive treatment for Hepatitis C ... last several months (May through August 2014) there has ... utilization. This suggests another surge of patients will begin ... similar efficacy and shorter duration are introduced in the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4
... Event for Congressional Members and Staff Will Focus on Advances ... Research and Treatment of Lung Cancer in ... CTIC; MTAX:), along with the Society for Women,s Health,Research, the ... "Lung Cancer: Being Female Matters to Research," on,Capitol Hill to ...
... in cSSSI, CAMBRIDGE, Mass., Sept. 13 ... Phase 2 trial,investigating the safety and efficacy of ... of Complicated Skin and Skin Structure,Infections (cSSSI), or ... positive infections. This Phase 2 study is ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 3Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 2Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 3
(Date:9/17/2014)... like the ideas of a science fiction writer, ... exciting new approach to imaging local and metastatic ... cancer, scientists at Virginia Commonwealth University Massey Cancer ... Hopkins Medical Institutions have provided proof-of-principle of a ... ability to see tumors that have metastasized to ...
(Date:9/17/2014)... 17, 2014 Catalent Pharma Solutions, ... and development solutions for drugs, biologics and consumer ... an integrated service and technology offer based on ... from the company’s 450,000 sq. ft. Kansas City, ... to integrate optimal formulation, development, analytical expertise, scale ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
Breaking Medicine News(10 mins):Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2
... A new technology called the Cone beam computerized tomography ... to diagnose complicated oral problems.// ,J. Martin ... at the Case Western Reserve University School of Dental ... department of dental health and biological sciences at the ...
... two protein complexes which is found to protect cell ... number of chromosomes leading to cell instability which leads ... research team from Mayo Clinic have found that the ... which maintains the euploidy state in the cell and ...
... The waiting times at Ontario’s hospitals are getting longer, according ... revealed by Elizabeth Witmer, the Conservative health critic.// The waiting ... and September 2005 for cancer surgery, while it rose from ... time increased to 22 days for cardiac surgeries, while in ...
... genetic code is reported to have been cracked by ... faster diagnosis and treatment of the ailment which causes ... Jewish General Hospital’s Dasval. The strain has caused infections ... The search can now commence for the other antibiotic ...
... Institute (SERI) found that increasing the contrast of details ... the visually impaired. // ,The U.S. study provides ... help millions suffering eye diseases. People who may benefit ... degeneration, diabetic retinopathy and other causes of low vision. ...
... National Laboratories, Gerry Yonas was the first to visualize a need ... the development of the BiNational Sustainability Laboratory (BNSL), which extends over ... mainly augment the border security force and deal with terrorism ... ,The monetary inputs for the lab come from USA, ...
Cached Medicine News:Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
Cold light source single outlet....
Cold light source triple outlet....
Cold light source single outlet....
... is a state of the ... source with an integrated intensity ... to connect optical fiber light ... itself from all others by ...
Medicine Products: